Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 3
2021 4
2022 7
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.
Papakonstantinou A, Gonzalez NS, Pimentel I, Suñol A, Zamora E, Ortiz C, Espinosa-Bravo M, Peg V, Vivancos A, Saura C, Villacampa G, Oliveira M. Papakonstantinou A, et al. Among authors: gonzalez ns. Cancer Treat Rev. 2022 Mar;104:102362. doi: 10.1016/j.ctrv.2022.102362. Epub 2022 Feb 18. Cancer Treat Rev. 2022. PMID: 35219090 Review.
New Insights into Adjuvant Therapy for Localized Colon Cancer.
González NS, Ros Montaña FJ, Illescas DG, Argota IB, Ballabrera FS, Élez Fernández ME. González NS, et al. Hematol Oncol Clin North Am. 2022 Jun;36(3):507-520. doi: 10.1016/j.hoc.2022.02.006. Epub 2022 May 13. Hematol Oncol Clin North Am. 2022. PMID: 35577707 Review.
Up-to-date role of aflibercept in the treatment of colorectal cancer.
Saoudi Gonzalez N, Salvà F, Ros J, Baraibar I, Marmolejo D, Valdivia A, Cuadra-Urteaga JL, Mulet N, Tabernero J, Élez E. Saoudi Gonzalez N, et al. Expert Opin Biol Ther. 2021 Oct;21(10):1315-1324. doi: 10.1080/14712598.2021.1935231. Epub 2021 Jun 13. Expert Opin Biol Ther. 2021. PMID: 34085884 Review.
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials.
Hernando-Calvo A, Vila-Casadesús M, Bareche Y, Gonzalez-Medina A, Abbas-Aghababazadeh F, Lo Giacco D, Martin A, Saavedra O, Brana I, Vieito M, Fasani R, Stagg J, Mancuso F, Haibe-Kains B, Han M, Berche R, Pugh TJ, Mirallas O, Jimenez J, Gonzalez NS, Valverde C, Muñoz-Couselo E, Suarez C, Diez M, Élez E, Capdevila J, Oaknin A, Saura C, Macarulla T, Galceran JC, Felip E, Dienstmann R, Bedard PL, Nuciforo P, Seoane J, Tabernero J, Garralda E, Vivancos A. Hernando-Calvo A, et al. Among authors: gonzalez ns. Med. 2023 Oct 13;4(10):710-727.e5. doi: 10.1016/j.medj.2023.07.006. Epub 2023 Aug 11. Med. 2023. PMID: 37572657 Free article.
21 results